Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
Liver Cancer. 2020 Dec;9(6):629-639. doi: 10.1159/000512170. Epub 2020 Oct 26.
Abstract
摘要
相似文献
1
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma.
Liver Cancer. 2020 Dec;9(6):629-639. doi: 10.1159/000512170. Epub 2020 Oct 26.
2
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
3
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30.
4
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Lung Cancer (Auckl). 2017 Jul 13;8:67-78. doi: 10.2147/LCTT.S113177. eCollection 2017.
5
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22.
6
The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.
Cancers (Basel). 2021 Jan 11;13(2):238. doi: 10.3390/cancers13020238.
7
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Oncotarget. 2017 Jun 20;8(25):41242-41255. doi: 10.18632/oncotarget.17168.
8
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Nat Med. 2018 Jun;24(6):749-757. doi: 10.1038/s41591-018-0053-3. Epub 2018 Jun 4.
9
[Immunotherapy for renal cell carcinoma - current status].
Aktuelle Urol. 2018 Apr;49(2):187-191. doi: 10.1055/a-0581-4451. Epub 2018 Mar 27.
10
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.
Cancers (Basel). 2019 Oct 14;11(10):1554. doi: 10.3390/cancers11101554.
引用本文的文献
1
Treatment Outcomes of Systemic Therapies for Infiltrative Hepatocellular Carcinoma.
J Hepatocell Carcinoma. 2025 Jun 23;12:1221-1229. doi: 10.2147/JHC.S528897. eCollection 2025.
2
Immunotherapy targeting liver cancer tumor-initiating cells: challenges, mechanisms, and emerging therapeutic horizons.
Front Immunol. 2025 Jun 11;16:1621243. doi: 10.3389/fimmu.2025.1621243. eCollection 2025.
3
Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis.
J Cancer Res Clin Oncol. 2025 Jun 25;151(6):196. doi: 10.1007/s00432-025-06233-7.
4
Effectiveness and safety of angiogenesis inhibitors combined with PD-1/PD-L1 blockades in the first-line treatment of patients with advanced hepatocellular carcinoma: A single-center retrospective study.
Medicine (Baltimore). 2025 Mar 14;104(11):e41814. doi: 10.1097/MD.0000000000041814.
5
Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating Nanovaccine Activates Anticancer Immunity.
Cancer Res. 2024 Nov 15;84(22):3834-3847. doi: 10.1158/0008-5472.CAN-24-0220.
6
A comprehensive pan-cancer analysis revealing the role of ITPRIPL1 as a prognostic and immunological biomarker.
Front Mol Biosci. 2024 Aug 15;11:1452290. doi: 10.3389/fmolb.2024.1452290. eCollection 2024.
7
Transarterial Embolization Enhances Programmed Cell Death Ligand 1 Expression and Influences CD8T Lymphocytes Cytotoxicity in an Orthotopic Hepatocellular Carcinoma Rat Model.
Cardiovasc Intervent Radiol. 2024 Oct;47(10):1372-1381. doi: 10.1007/s00270-024-03813-x. Epub 2024 Aug 5.
8
Hepatocellular Carcinoma: Beyond the Border of Advanced Stage Therapy.
Cancers (Basel). 2024 May 27;16(11):2034. doi: 10.3390/cancers16112034.
9
Recurrence risk stratification of hepatocellular carcinomas based on immune gene expression and features extracted from pathological images.
PLoS Comput Biol. 2023 Dec 29;19(12):e1011716. doi: 10.1371/journal.pcbi.1011716. eCollection 2023 Dec.
10
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406.
本文引用的文献
1
Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma.
Liver Cancer. 2020 Sep;9(5):479-490. doi: 10.1159/000509554. Epub 2020 Aug 20.
2
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.
Liver Cancer. 2020 Aug;9(4):426-439. doi: 10.1159/000506352. Epub 2020 Mar 17.
3
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
4
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
5
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.
Liver Cancer. 2019 Nov;8(6):413-426. doi: 10.1159/000503254. Epub 2019 Sep 27.
6
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
7
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.
Cancers (Basel). 2020 Apr 27;12(5):1089. doi: 10.3390/cancers12051089.
8
Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma.
Pathol Int. 2020 Mar;70(3):140-154. doi: 10.1111/pin.12895. Epub 2020 Jan 6.
9
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2.
10
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.
Zotero 插件